Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Investor Presentation (November 2026)
33 slides from Arbutus Biopharma's investor presentation, Nov 12, 2026
Slide 1: Corporate Presentation Q4 2026
© 2026 ARBUTUS BIOPHARMA, INC 1 WWW.ARBUTUSBIO.COM © 2026 ARBUTUS BIOPHARMA, INC CORPORATE PRESENTATION Q4 2026 NASDAQ: ABUS
Slide 2: Forward-Looking Statements
© 2026 ARBUTUS BIOPHARMA, INC 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as
Slide 3: Arbutus Biopharma Overview
© 2026 ARBUTUS BIOPHARMA, INC Agenda 3 Arbutus Biopharma Overview Our team includes leaders with the deep scientific and development expertise needed to accelerate and strengthen our portfolio’s path to market Focused on Developing a Functional Cure for Patients with Chronic Hepatitis B (cHBV) Cash
Slide 4: Pipeline Overview
© 2026 ARBUTUS BIOPHARMA, INC 4 Pipeline Overview Imdusiran siRNA Therapeutic (Subcutaneous) cHBV Program Phase 1 Phase 2 Phase 3 AB - 101 - 001 AB - 101 in healthy volunteers & cHBV patients PEG - IFNα : Pegylated Interferon Alfa - 2a | NA : Nucleos (t)ide Analogue | VTP - 300 : Barinthus Biotherap
Slide 5: cHBV is a Potentially Fatal Disease and Significant Worldwide Commercial Opportunity
© 2026 ARBUTUS BIOPHARMA, INC Americas 5M Europe 9.7M China & Western Pacific Asia 102M Africa 64M Eastern Mediterranean 16M Southeast Asia 43M 5 cHBV is a Potentially Fatal Disease and Represents a Significant Worldwide Commercial Opportunity Worldwide, approximately 240 million people are living w
Slide 6: Functional Cure Used as Primary Endpoint in Pivotal Trials of Novel HBV Therapies
© 2026 ARBUTUS BIOPHARMA, INC 6 Functional Cure Used as Primary Endpoint in Pivotal Trials of Novel HBV Therapies • Functional cure is defined as sustained HBsAg seroclearance and undetectable HBV DNA off all therapy for 24 weeks • HBsAg seroclearance is associated with reduction of disease progress
Slide 7: Functional Cure Rates Remain Low with Existing Treatments
© 2026 ARBUTUS BIOPHARMA, INC 7 HBsAg Seroclearance & Functional Cure Rates Remain Low with Existing Treatments • Current options fall into three categories: NA therapy, PEG - IFNα and bepirovirsen (approved Oct '26) • NA therapy curbs viral replication and HBV DNA, but most patients need to stay on
Slide 8: RNAi Therapeutic Imdusiran
© 2026 ARBUTUS BIOPHARMA, INC © 2026 ARBUTUS BIOPHARMA, INC RNAi Therapeutic Imdusiran
Slide 9: Imdusiran: siRNA Designed to Target HBV in the Liver
© 2026 ARBUTUS BIOPHARMA, INC 9 Imdusiran: siRNA Designed to Target HBV in the Liver • GalNAc - conjugated siRNA agent administered subcutaneously • Efficient and specific ASGPR binding on liver cells • Inhibits viral replication by silencing all HBV transcripts: • Lowers HBV DNA and HBV - derived a
Slide 10: Imdusiran is Designed for Potential Best-In-Class Anti-HBV siRNA
© 2026 ARBUTUS BIOPHARMA, INC Terminal modification GalNAc Ligand 10 Imdusiran is Designed for Potential Best - In - Class Anti - HBV siRNA Properties • Proprietary tetravalent GalNAc provides highly efficient liver - targeted uptake by ASGPR • Single trigger agent with unique potency and enhanced d
Slide 11: Key Outcomes Across Imdusiran Studies
© 2026 ARBUTUS BIOPHARMA, INC Key Outcomes Arms Population Evaluable Patients Phase Study • Single dose imdusiran was safe and well - tolerated in healthy volunteers SAD imdusiran at 60, 180, and 360 mg Healthy Volunteers 12 1a AB - 729 - 001 • SAD and MAD imdusiran well - tolerated in cHBV patients
Slide 12: Imdusiran Potentially Demonstrates Best-In-Class Safety and Patient Convenience
© 2026 ARBUTUS BIOPHARMA, INC 12 Imdusiran Potentially Demonstrates Best - In - Class Safety and Patient Convenience Generally Safe and Well - Tolerated in Over 250 Patients Who Have Received imdusiran in Clinical Trials For patients receiving repeat doses of imdusiran in our clinical trials: • Ther
Slide 13: AB-729-001: Phase 1a/1b Open-Label, Multi-Center Clinical Trial
© 2026 ARBUTUS BIOPHARMA, INC 13 AB - 729 - 001: A Phase 1a/1b Open - Label, Multi - Center Clinical Trial Imdusiran alone or in combination with NA therapy over multiple dose levels and durations Part 1: (n=6/cohort, 2:1 Placebo:Active) Part 1: SAD Healthy Volunteers Part 2: (n=7 - 8/cohort, open -
Slide 14: AB-729-001/Phase 1b: Robust HBsAg Decreases with Imdusiran
© 2026 ARBUTUS BIOPHARMA, INC • Imdusiran was well - tolerated with no drug - related SAEs or discontinuations due to related AEs at all dose levels and durations • HBsAg reduction was observed in all patients, regardless of baseline HBsAg levels, HBV DNA +/ - status and HBeAg +/ - status • 44/62 (7
Slide 15: Phase 1b: Multiple Ascending Dose Arms See Robust HBsAg Decreases
© 2026 ARBUTUS BIOPHARMA, INC 15 AB - 729 - 001/Phase 1b: Multiple Ascending Dose Arms See Robust HBsAg Decreases Across All HBsAg Baseline Levels, HBeAg +/ - Status and HBV DNA +/ - Status • Across all cohorts, HBsAg mean decrease was 99% ( - 2.0 log) after imdusiran dosing up to week 48 (from me
Slide 16: Imdusiran Mediates Dose Dependent HBeAg Decline in HBeAg+ Patients
© 2026 ARBUTUS BIOPHARMA, INC 16 Imdusiran Mediates Dose Dependent HBeAg Decline in HBeAg+ Patients, Who Typically Have Very Active Disease and Poor Clinical Outcomes 30 HBeAg+ patients received imdusiran in Phase 1a/1b and IM - PROVE II clinical trials: • HBeAg decreased in all patients in a dose -
Slide 17: Imdusiran Demonstrates Steep and Durable Declines in HBV DNA
© 2026 ARBUTUS BIOPHARMA, INC 17 Imdusiran Demonstrates Steep and Durable Declines in HBV DNA B a s e l i n e W e e k 1 8 W e e k 4 8 B a s e l i n e W e e k 1 8 W e e k 4 8 0 50,000 100,000 150,000 200,000 H B V D N A ( I U / m L ) 90 mg Single Dose w/o NA (N=5) 90 mg Q8W w/ NA (N=7) In Phase 1b
Slide 18: IM-PROVE I: Phase 2a Trial of Imdusiran and PEG-IFNα
© 2026 ARBUTUS BIOPHARMA, INC Imdusiran in combination with ongoing NA therapy and short courses of PEG - IFNα 18 IM - PROVE I: A Phase 2a Open - Label, Multi - Center Clinical Trial of imdusiran and PEG - IFNα NA only Follow - up 24 weeks A1: Imdusiran x 2 doses + PEG - IFN α x24 w eeks (n=12) A2:
Slide 19: IM-PROVE I: Total Functional Cure and NA Therapy Discontinuation
© 2026 ARBUTUS BIOPHARMA, INC 19 Total Functional Cure and NA Therapy Discontinuation Treatment regimen* Imdusiran (60 mg) x6 doses + PEG - IFN α x24 weeks Cohort A1 Imdusiran (60 mg) x4 doses + PEG - IFN α x24 weeks Cohort A2 Imdusiran (60 mg) x5 doses + PEG - IFN α x12 weeks Cohort B1 Imdusiran (6
Slide 20: IM-PROVE I: Functional Cure with Half the Approved PEG-IFNα Duration
© 2026 ARBUTUS BIOPHARMA, INC 20 IM - PROVE I: Imdusiran (60 mg) Achieves Functional Cure with Only Half the Approved Duration of PEG - IFNα Therapy (24 vs. 48 Weeks) Imdusiran plus 24 weeks of PEG - IFNα was generally safe and well - tolerated – no SAEs; no AEs leading to discontinuation • Absence
Slide 21: IM-PROVE II: Phase 2a Trial of Imdusiran Plus Immunotherapeutics
© 2026 ARBUTUS BIOPHARMA, INC Imdusiran in combination with ongoing NA therapy followed by immunotherapeutics 21 IM - PROVE II: A Phase 2a Multi - Center Clinical Trial of imdusiran Plus Immunotherapeutics Group B : VTP - 300 placebo (n=20) Weeks 1 Imdusiran x 4 doses 60 mg Q8W (n=40) Imdusiran x 4
Slide 22: IM-PROVE II: Imdusiran and a PD-1 Inhibitor Achieved Functional Cures
© 2026 ARBUTUS BIOPHARMA, INC 22 IM - PROVE II: A Combination of imdusiran (60 mg) and a PD - 1 Inhibitor Achieved Functional Cures • Imdusiran again demonstrated rapid and deep HBsAg declines in patients on background NA therapy • 3/13 patients (23%) achieved HBsAg seroclearance after imdusiran tre
Slide 23: IM-PROVE II: 52% Achieved Functional Cure or Discontinued NA Therapy
© 2026 ARBUTUS BIOPHARMA, INC 23 IM - PROVE II: 52% of Patients Either Achieved Functional Cure or Were Able to Discontinue NA Therapy With imdusiran at 60 mg *All patients were on NA background therapy Total Functional Cure and NA Therapy Discontinuation (48 weeks) Treatment regimen* Imdusiran ( 60
Slide 24: Imdusiran Demonstrates Remarkable Durability in Long-Term Follow-Up
© 2026 ARBUTUS BIOPHARMA, INC Functional Cure Off NA Therapy 146+ wks 137+ wks 132+ wks 132+ wks 117+ wks 118+ wks 107+ wks 106+ wks 146+ wks 145+ wks 143+ wks 142+ wks 144+ wks 143+ wks 142+ wks 89+ wks 73+ wks 131+ wks 60+ wks A B C D E F G H I J K L M N O P Q R S Partial Cure 24 Imdusiran Demonst
Slide 25: Imdusiran Has the Potential to Set a New Benchmark in cHBV Treatment
© 2026 ARBUTUS BIOPHARMA, INC 25 Imdusiran has the Potential to Set a New Benchmark in cHBV Treatment • Well - tolerated in over 250 patients who have received imdusiran across clinical trials. For patients receiving repeat doses of imdusiran : • No related SAEs reported and no safety - related disc
Slide 26: Applying FDA 'Blips' Concept, Imdusiran Would Likely Achieve Additional Functional Cure
© 2026 ARBUTUS BIOPHARMA, INC 26 If We Apply the Concept of "Blips" From the Definition of Functional Cure the FDA Used for Hibsago , imdusiran Would Likely Achieve An Additional Functional Cure • Transient post - treatment recurrences of HBsAg or HBV DNA (‘blips’) can occur during clinical monitori
Slide 27: Oral PD-L1 Checkpoint Inhibitor AB-101
© 2026 ARBUTUS BIOPHARMA, INC © 2026 ARBUTUS BIOPHARMA, INC Oral PD - L1 Checkpoint Inhibitor AB - 101
Slide 28: AB-101: A Differentiated Oral PD-L1 Inhibitor Designed for Safety
© 2026 ARBUTUS BIOPHARMA, INC Differentiated Approach with Potentially Superior Safety Profile* Validated Mechanism of Action and Potent Activity Confirmed target engagement in humans: Clear, dose - dependent PD - L1 receptor occupancy, maximal (100%) at 40 mg dose Optimal PK for once - daily dosing
Slide 29: Mechanism of Action for AB-101
© 2026 ARBUTUS BIOPHARMA, INC 29 Mechanism of Action for AB - 101 Created in https://BioRender.com
Slide 30: AB-101: First-in-Human Phase 1a/1b Clinical Trial
© 2026 ARBUTUS BIOPHARMA, INC 30 AB - 101: A First - in - Human Phase 1a/1b Clinical Trial Parts 1 & 2: Healthy Volunteers Part 3: cHBV Patients Part 1: SAD (n=8/cohort – 6:2) Part 2: MAD (n=10/cohort – 8:2) Part 3: cHBV Patients (n=12/cohort – 10:2) Virally suppressed 1A: 1 mg 1B: 3 mg 1C: 10 mg 1D
Slide 31: Over 80% of Patients Reached Full PD-L1 Occupancy with AB-101 at 40 mg
© 2026 ARBUTUS BIOPHARMA, INC 31 Over 80% of Patients Reached Full PD - L1 Occupancy with AB - 101 at 40 mg • Receptor occupancy increased in a dose - dependent manner • Across SAD and MAD cohorts, 11 of 13 (84.6%) evaluable healthy subjects receiving single or multiple 40 mg doses of AB - 101 achie
Slide 32: Oral AB-101 is Well-Absorbed with PK Supporting Once Daily Dosing
© 2026 ARBUTUS BIOPHARMA, INC 32 Oral AB - 101 is Well - Absorbed with Pharmacokinetics (PK) Supporting Once Daily Dosing • AB - 101 appeared rapidly in plasma following oral dosing • Maximum AB - 101 concentrations achieved at 1 - 3 hours post - dose • Terminal half - life >20 hours at doses ≥25 mg
Slide 33: ARBUTUSBIO.COM
© 2026 ARBUTUS BIOPHARMA, INC © 2025 ARBUTUS BIOPHARMA, INC © 2026 ARBUTUS BIOPHARMA, INC 33 NASDAQ: ABUS ARBUTUSBIO.COM
Arbutus Biopharma — Investor Presentation (November 2026) on 6ix